CMS Sees “Similar” Payments For “Similar” Products In Upcoming OPPS Rule
Executive Summary
The Centers for Medicare & Medicaid Services' upcoming proposed Hospital Outpatient Prospective Payment System rule is likely to include "similar" levels of reimbursement for therapies that have "similar clinical effects," Office of Clinical Standards & Quality Acting Director Sean Tunis, MD, said
You may also be interested in...
CMS Defends “Functional Equivalence”; AWP Proposal Ready, Scully Says
The Centers for Medicare & Medicaid Services is sticking to its position that deeming Amgen's Aranesp "functionally equivalent" to Johnson & Johnson's Procrit is the best approach to handling the product under the Hospital Outpatient Prospective Payment System
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011